S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway

Quince Therapeutics (QNCX) Competitors

$1.28
-0.02 (-1.54%)
(As of 03/1/2024 ET)

QNCX vs. FIXX, BIVI, CADL, DTIL, ALGS, BIOR, IKNA, ESLA, ELYM, and TPST

Should you be buying Quince Therapeutics stock or one of its competitors? The main competitors of Quince Therapeutics include Homology Medicines (FIXX), BioVie (BIVI), Candel Therapeutics (CADL), Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), Biora Therapeutics (BIOR), Ikena Oncology (IKNA), Estrella Immunopharma (ESLA), Eliem Therapeutics (ELYM), and Tempest Therapeutics (TPST). These companies are all part of the "medical" sector.

Quince Therapeutics vs.

Homology Medicines (NASDAQ:FIXX) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Homology Medicines received 125 more outperform votes than Quince Therapeutics when rated by MarketBeat users.

CompanyUnderperformOutperform
Homology MedicinesOutperform Votes
125
64.43%
Underperform Votes
69
35.57%
Quince TherapeuticsN/AN/A

In the previous week, Homology Medicines had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 2 mentions for Homology Medicines and 1 mentions for Quince Therapeutics. Homology Medicines' average media sentiment score of 1.89 beat Quince Therapeutics' score of 0.93 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Homology Medicines Positive
Quince Therapeutics Very Positive

Homology Medicines presently has a consensus target price of $9.50, indicating a potential upside of 963.71%. Given Quince Therapeutics' higher probable upside, equities research analysts clearly believe Homology Medicines is more favorable than Quince Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Homology Medicines
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Quince Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Homology Medicines has a beta of -0.11, indicating that its stock price is 111% less volatile than the S&P 500. Comparatively, Quince Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500.

30.0% of Homology Medicines shares are owned by institutional investors. Comparatively, 39.6% of Quince Therapeutics shares are owned by institutional investors. 16.1% of Homology Medicines shares are owned by company insiders. Comparatively, 21.0% of Quince Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quince Therapeutics has a net margin of 0.00% compared to Quince Therapeutics' net margin of -4,779.31%. Homology Medicines' return on equity of -31.07% beat Quince Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Homology Medicines-4,779.31% -97.60% -71.29%
Quince Therapeutics N/A -31.07%-30.18%

Homology Medicines has higher revenue and earnings than Quince Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Homology Medicines$1.96M26.37-$5.01M-$2.28-0.39
Quince TherapeuticsN/AN/A-$51.66MN/AN/A

Summary

Quince Therapeutics beats Homology Medicines on 7 of the 13 factors compared between the two stocks.


Get Quince Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for QNCX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QNCX vs. The Competition

MetricQuince TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$54.87M$2.75B$5.20B$7.62B
Dividend YieldN/A2.38%2.82%3.87%
P/E RatioN/A22.18204.1516.27
Price / SalesN/A267.423,035.5480.31
Price / CashN/A31.2299.4255.35
Price / Book0.464.474.534.54
Net Income-$51.66M-$6.05M$114.95M$211.55M
7 Day Performance-3.76%5.86%5.70%3.36%
1 Month Performance-3.76%15.45%11.24%6.68%
1 Year Performance28.00%12.77%14.08%8.85%

Quince Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FIXX
Homology Medicines
4.5824 of 5 stars
$0.92
+2.2%
$9.50
+938.3%
-38.4%$52.90M$3.21M-0.4092
BIVI
BioVie
1.9603 of 5 stars
$1.27
+3.3%
$8.00
+529.9%
-69.9%$50.64MN/A-1.0918Options Volume
News Coverage
Gap Up
CADL
Candel Therapeutics
2.3969 of 5 stars
$1.74
-2.2%
$9.00
+417.2%
-5.6%$50.32M$120,000.00-1.5876Short Interest ↑
Gap Down
DTIL
Precision BioSciences
4.5291 of 5 stars
$16.04
+0.3%
$90.00
+461.1%
-62.8%$65.12M$52.29M-0.81115Short Interest ↓
News Coverage
Gap Down
ALGS
Aligos Therapeutics
3.7382 of 5 stars
$0.95
+4.4%
N/A-23.4%$71.18M$13.91M-0.5168Short Interest ↓
Gap Up
High Trading Volume
BIOR
Biora Therapeutics
0.5434 of 5 stars
$1.54
+46.7%
N/A-63.5%$41.90M$310,000.00-0.1654Gap Up
High Trading Volume
IKNA
Ikena Oncology
2.8041 of 5 stars
$1.51
-0.7%
$10.67
+606.4%
-63.8%$72.87M$15.62M-0.9357Short Interest ↑
High Trading Volume
ESLA
Estrella Immunopharma
0 of 5 stars
$1.04
-1.9%
N/AN/A$38.07MN/A0.00N/AShort Interest ↑
Positive News
Gap Down
ELYM
Eliem Therapeutics
2.1274 of 5 stars
$2.75
+4.2%
$6.00
+118.2%
-22.7%$75.82MN/A-1.8730Upcoming Earnings
Positive News
TPST
Tempest Therapeutics
1.2916 of 5 stars
$3.94
-0.5%
$20.50
+420.3%
+125.8%$75.85MN/A-1.7919Gap Up

Related Companies and Tools

This page (NASDAQ:QNCX) was last updated on 3/3/2024 by MarketBeat.com Staff